Compare DexCom, Inc. (DXCM) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Lemonade Inc — how do they compare? DexCom, Inc. trades at $90.7 (market cap $33.79B), while Lemonade Inc trades at $51.83 (market cap $4.09B). The key difference: DexCom, Inc. is far larger — about 8.3× Lemonade Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | LMND | |
|---|---|---|
Market Cap | $33.79B | $4.09B |
Sector | Health | Financials |
52-Week High | $89.53 | $96.57 |
52-Week Low | $54.84 | $47.38 |
Enterprise Value | $33.24B | $3.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Lemonade (LMND) trades at $51.21, down 2.79% in the past 24 hours, with a bearish technical signal indicated by moving averages and ADX. The company reported Q2 2026 earnings that beat expectations, with revenue growth of 79% year-over-year, but remains unprofitable with a net income margin of -14.19%. Recent news highlights a CFO transition and expansion into new states, while the stock faces volatility amid mixed analyst sentiment.
The outlook for LMND hinges on achieving profitability, guided for Q4 2026, but high valuation (P/S of 4.1) and persistent losses pose risks. Opportunities include AI-driven growth and market expansion, yet investors face execution risks and competitive pressures in the insurance sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
